Skip to content
The Great News – Lifestyle
Home
Sample Page
Author:
NEUROCRINE BIOSCIENCES, INC.
Neurocrine Biosciences Launches Interactive Educational Resources to Support Clinical Learning in Classic Congenital Adrenal Hyperplasia
October 30, 2026
Neurocrine Biosciences Presents New Analysis Establishing Benchmark for Clinically Meaningful Change in Overall Health Reported by Patients with Tardive Dyskinesia
October 26, 2026
Neurocrine Biosciences Announces Publication in Orphanet Journal of Rare Diseases Advancing Understanding of Hyperphagia in Prader-Willi Syndrome
October 22, 2026
Neurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal Hyperplasia
October 20, 2026
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-‘567 in Adults with Alzheimer’s Disease
October 20, 2026
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results
October 12, 2026
Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference
September 30, 2026
Neurocrine Biosciences to Present at Upcoming Investor Conferences in September
September 2, 2026
Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia
August 12, 2026
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-‘1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist
August 7, 2026
1
2
3
Next Page
→